Baker Brothers portfolio, Q3 2024
Baker Bros. Advisors · 13F for the quarter ending Sep 30, 2024
For Q3 2024, Baker Bros. Advisors reported $9.6B across 93 US-listed positions, led by ONC (24.6%), INCY (21.1%) and ACAD (6.8%). Compared with its filing for Q2 2024, Baker Brothers opened 5 new positions, added to 16, reduced 2 and sold out of 7; 69 positions did not change.
The largest purchase was an addition to INSM ($61.3M); the largest sale, the sale of the whole position in Insmed Incorporated ($56.2M).
Key facts
- 13F portfolio value
- $9.6BQ3 2024
- Positions
- 93
- Largest holding
- ONC 24.6%
- New positions
- 5
- Sold out
- 7
- Filed
- Nov 14, 2024
Holdings as of (Q3 2024), filed with the SEC on . Changes are measured against the filing for Jun 30, 2024. Every tracked investor's Q3 2024 13F.
Bought and sold in Q3 2024
| Stock | Move | Shares | Size | Of portfolio |
|---|---|---|---|---|
| Insmed IncINSM | ▲ Added 23% | +839.88K | $61.3M | 0.64% |
Insmed Incorporatedno ticker on file | ▼ Sold out | — | $56.2M | 0.58% |
| CRISPR Therapeutics AGCRSP | ▲ Added 743% | +743.08K | $34.9M | 0.36% |
HOOKIPA Pharma Incno ticker on file | ▼ Reduced 90% | −7.32M | $31.5M | 0.33% |
Cerevel Therapeutics Hldngno ticker on file | ▼ Sold out | −683.59K | $28M | 0.29% |
| Summit Therapeutics IncSMMT | ▲ Added 5.2% | +1.2M | $26.3M | 0.27% |
| Immunovant IncIMVT | ▲ Added 164% | +760.69K | $21.7M | 0.22% |
| Bicara Therapeutics IncBCAX | ▲ New | +833.33K | $21.2M | 0.22% |
| Praxis Precision MedicinesPRAX | ▲ Added 146% | +191.57K | $11M | 0.11% |
| Replimune Group IncREPL | ▲ Added 10.0% | +1M | $11M | 0.11% |
Centessa Pharmaceuticals PLCno ticker on file | ▲ Added 123% | +677.97K | $10.8M | 0.11% |
| Arvinas IncARVN | ▲ New | +405.58K | $10M | 0.10% |
| Ionis Pharmaceuticals IncIONS | ▲ New | +223.47K | $9M | 0.09% |
Athira Pharma Incno ticker on file | ▼ Sold out | −3.15M | $8.4M | 0.09% |
| Ultragenyx PharmaceuticalRARE | ▲ Added 7.5% | +109.57K | $6.1M | 0.06% |
Talis Biomedical Corpno ticker on file | ▼ Sold out | −508.32K | $4.4M | 0.05% |
| Structure Therapeutics IncGPCR | ▲ New | +85.5K | $3.8M | 0.04% |
| Skye Bioscience IncSKYE | ▲ Added 187% | +934.63K | $3.7M | 0.04% |
| Wave Life Sciences LtdWVE | ▲ New | +344.06K | $2.8M | 0.03% |
| Xencor IncXNCR | ▲ Added 23% | +125K | $2.5M | 0.03% |
Adaptimmune Therapeuticsno ticker on file | ▼ Sold out | −2.34M | $2.3M | 0.02% |
Sage Therapeutics Incno ticker on file | ▼ Sold out | −171.03K | $1.9M | 0.02% |
Generation Bio Cono ticker on file | ▲ Added 61% | +737.99K | $1.8M | 0.02% |
Achilles Therapeutics plcno ticker on file | ▼ Sold out | −1.11M | $903.6K | 0.01% |
| Design Therapeutics IncDSGN | ▲ Added 2.9% | +48.43K | $260.6K | 0.00% |
IGM Biosciences Incno ticker on file | ▲ Added 0.05% | +1.99K | $33K | 0.00% |
| Incyte CorpINCY | ▲ Added 0.00% | +496 | $32.8K | 0.00% |
| Newamsterdam Pharma CompanyNAMS | ▼ Reduced 0.1% | −116 | $1.9K | 0.00% |
| Rhythm Pharmaceuticals IncRYTM | ▲ Added 0.00% | +1 | $52.4 | 0.00% |
| Kymera Therapeutics IncKYMR | ▲ Added 0.00% | +1 | $47.3 | 0.00% |
Holdings at the quarter's end
| # | Stock | Sector | Share of portfolio | Value | Shares | Reported price | Held | Since Q2 2024 |
|---|---|---|---|---|---|---|---|---|
| 1 | Beone Medicines LtdONC · SPONSORED ADS | Health Care | 24.6% | $2.4B | 10.57M | $224.51 | 2+ qtrs | No change |
| 2 | Incyte CorpINCY | Health Care | 21.1% | $2B | 30.74M | $66.10 | 2+ qtrs | ▲ Added 0.00% |
| 3 | Acadia Pharmaceuticals IncACAD | — | 6.84% | $659.5M | 42.88M | $15.38 | 2+ qtrs | No change |
| 4 | Summit Therapeutics IncSMMT | Health Care | 5.54% | $534.9M | 24.42M | $21.90 | 2+ qtrs | ▲ Added 5.2% |
| 5 | Madrigal Pharmaceuticals IncMDGL | Health Care | 4.34% | $419M | 1.97M | $212.22 | 2+ qtrs | No change |
| 6 | Revolution Medicines IncRVMD | Health Care | 3.56% | $343.3M | 7.57M | $45.35 | 2+ qtrs | No change |
| 7 | Rhythm Pharmaceuticals IncRYTM | Health Care | 3.47% | $335.2M | 6.4M | $52.39 | 2+ qtrs | ▲ Added 0.00% |
| 8 | Insmed IncINSM | Health Care | 3.34% | $322.4M | 4.42M | $73.00 | 2+ qtrs | ▲ Added 23% |
| 9 | Kymera Therapeutics IncKYMR | Health Care | 2.94% | $283.8M | 6M | $47.33 | 2+ qtrs | ▲ Added 0.00% |
| 10 | Bicycle Therapeutics PlcBCYC · SPONSORED ADS | — | 2.21% | $212.7M | 9.4M | $22.63 | 2+ qtrs | No change |
| 11 | Edgewise Therapeutics IncEWTX | Health Care | 1.62% | $155.9M | 5.84M | $26.69 | 2+ qtrs | No change |
| 12 | Replimune Group IncREPL | — | 1.26% | $121.1M | 11.05M | $10.96 | 2+ qtrs | ▲ Added 10.0% |
| 13 | Alkermes PLCALKS · SHS | Health Care | 1.21% | $117M | 4.18M | $27.99 | 2+ qtrs | No change |
| 14 | Denali Therapeutics IncDNLI | — | 1.13% | $108.7M | 3.73M | $29.13 | 2+ qtrs | No change |
| 15 | Insmed Incno ticker on file · NOTE 0.75% 6/1/2028 | — | 1.02% | $98.3M | — | — | 2+ qtrs | No change |
| 16 | Ultragenyx PharmaceuticalRARE | — | 0.91% | $87.6M | 1.58M | $55.55 | 2+ qtrs | ▲ Added 7.5% |
| 17 | Nurix Therapeutics IncNRIX | — | 0.90% | $87.2M | 3.88M | $22.47 | 2+ qtrs | No change |
| 18 | Entrada Therapeutics IncTRDA | — | 0.81% | $77.8M | 4.87M | $15.98 | 2+ qtrs | No change |
| 19 | Immatics N.V.IMTX · SHS | — | 0.76% | $73.5M | 6.44M | $11.41 | 2+ qtrs | No change |
| 20 | Abcellera Biologics IncABCL | — | 0.74% | $71.6M | 27.53M | $2.60 | 2+ qtrs | No change |
| 21 | Kiniksa Pharmaceuticals InternationalKNSA · ORD SHS CL A | Health Care | 0.73% | $70.4M | 2.82M | $24.99 | 2+ qtrs | No change |
| 22 | IGM Biosciences Incno ticker on file | — | 0.70% | $67.7M | 4.09M | $16.54 | 2+ qtrs | ▲ Added 0.05% |
| 23 | argenx SEARGX · SPONSORED ADR | Health Care | 0.63% | $60.7M | 111.9K | $542.08 | 2+ qtrs | No change |
| 24 | Stoke Therapeutics IncSTOK | — | 0.56% | $53.7M | 4.37M | $12.29 | 2+ qtrs | No change |
| 25 | Immunocore Holdings plcIMCR · ADS | — | 0.49% | $47.2M | 1.52M | $31.13 | 2+ qtrs | No change |
| 26 | Kodiak Sciences IncKOD | Health Care | 0.47% | $45.2M | 17.31M | $2.61 | 2+ qtrs | No change |
| 27 | Sera Prognostics IncSERA · CLASS A COM | — | 0.44% | $42.4M | 5.43M | $7.80 | 2+ qtrs | No change |
| 28 | CRISPR Therapeutics AGCRSP · NAMEN AKT | Health Care | 0.41% | $39.6M | 843.08K | $46.98 | 2+ qtrs | ▲ Added 743% |
| 29 | Xenon Pharmaceuticals IncXENE | — | 0.41% | $39.1M | 993.68K | $39.37 | 2+ qtrs | No change |
| 30 | Immunovant IncIMVT | Health Care | 0.36% | $34.9M | 1.23M | $28.51 | 2+ qtrs | ▲ Added 164% |
| 31 | Cerus CorpCERS | — | 0.35% | $33.9M | 19.48M | $1.74 | 2+ qtrs | No change |
| 32 | IDEAYA Biosciences IncIDYA | — | 0.35% | $33.6M | 1.06M | $31.68 | 2+ qtrs | No change |
| 33 | Roivant Sciences LtdROIV · SHS | Health Care | 0.34% | $32.3M | 2.8M | $11.54 | 2+ qtrs | No change |
| 34 | Akero Therapeutics Incno ticker on file | — | 0.33% | $31.5M | 1.1M | $28.69 | 2+ qtrs | No change |
| 35 | Krystal Biotech IncKRYS | Health Care | 0.32% | $30.9M | 169.93K | $182.03 | 2+ qtrs | No change |
| 36 | Celcuity IncCELC | — | 0.29% | $28M | 1.87M | $14.91 | 2+ qtrs | No change |
| 37 | Monte Rosa Therapeutics IncGLUE | — | 0.27% | $26.1M | 4.92M | $5.30 | 2+ qtrs | No change |
| 38 | Dyne Therapeutics IncDYN | — | 0.25% | $24.1M | 672.1K | $35.92 | 2+ qtrs | No change |
| 39 | Biomea Fusion IncBMEA | — | 0.22% | $21.3M | 2.11M | $10.10 | 2+ qtrs | No change |
| 40 | Bicara Therapeutics IncBCAX | — | 0.22% | $21.2M | 833.33K | $25.47 | 1 qtr | New |
| 41 | Prelude Therapeutics IncPRLD | — | 0.22% | $21M | 10.12M | $2.07 | 2+ qtrs | No change |
| 42 | Centessa Pharmaceuticals PLCno ticker on file · SPONSORED ADS | — | 0.20% | $19.6M | 1.23M | $15.99 | 2+ qtrs | ▲ Added 123% |
| 43 | Neurogene IncNGNE | — | 0.20% | $19.1M | 456.02K | $41.96 | 2+ qtrs | No change |
| 44 | Praxis Precision MedicinesPRAX | Health Care | 0.19% | $18.6M | 323.11K | $57.54 | 2+ qtrs | ▲ Added 146% |
| 45 | Alumis IncALMS | — | 0.17% | $16.7M | 1.56M | $10.68 | 2+ qtrs | No change |
| 46 | Merus N Vno ticker on file | — | 0.16% | $15M | 300K | $49.96 | 2+ qtrs | No change |
| 47 | TScan Therapeutics IncTCRX | — | 0.14% | $13.9M | 2.78M | $4.98 | 2+ qtrs | No change |
| 48 | Neumora Therapeutics IncNMRA | — | 0.14% | $13.7M | 1.03M | $13.21 | 2+ qtrs | No change |
| 49 | Xencor IncXNCR | — | 0.14% | $13.5M | 670.43K | $20.11 | 2+ qtrs | ▲ Added 23% |
| 50 | 2seventy bio Incno ticker on file | — | 0.12% | $11.8M | 2.5M | $4.72 | 2+ qtrs | No change |
| 51 | Fate Therapeutics IncFATE | — | 0.11% | $10.5M | 3M | $3.50 | 2+ qtrs | No change |
| 52 | Arvinas IncARVN | — | 0.10% | $10M | 405.58K | $24.63 | 1 qtr | New |
| 53 | Sana Biotechnology IncSANA | — | 0.10% | $9.9M | 2.38M | $4.16 | 2+ qtrs | No change |
| 54 | Design Therapeutics IncDSGN | — | 0.10% | $9.4M | 1.74M | $5.38 | 2+ qtrs | ▲ Added 2.9% |
| 55 | Ionis Pharmaceuticals IncIONS | Health Care | 0.09% | $9M | 223.47K | $40.06 | 1 qtr | New |
| 56 | Opthea Limitedno ticker on file · SPONSORED ADS | — | 0.09% | $8.8M | 2.17M | $4.07 | 2+ qtrs | No change |
| 57 | Celldex Therapeutics IncCLDX | — | 0.09% | $8.4M | 247.64K | $33.99 | 2+ qtrs | No change |
| 58 | Relay Therapeutics IncRLAY | — | 0.09% | $8.2M | 1.16M | $7.08 | 2+ qtrs | No change |
| 59 | Verve Therapeutics Incno ticker on file | — | 0.09% | $8.2M | 1.69M | $4.84 | 2+ qtrs | No change |
| 60 | Taysha Gene Therapies IncTSHA | — | 0.08% | $8M | 4M | $2.01 | 2+ qtrs | No change |
| 61 | Mirum Pharmaceuticals IncMIRM | Health Care | 0.08% | $7.4M | 190.48K | $39.00 | 2+ qtrs | No change |
| 62 | Contineum Therapeutics IncCTNM · CL A | — | 0.06% | $6M | 312.5K | $19.14 | 2+ qtrs | No change |
| 63 | Tango Therapeutics IncTNGX | — | 0.06% | $5.8M | 750K | $7.70 | 2+ qtrs | No change |
| 64 | Skye Bioscience IncSKYE | — | 0.06% | $5.6M | 1.43M | $3.91 | 2+ qtrs | ▲ Added 187% |
| 65 | Vaxcyte IncPCVX | Health Care | 0.06% | $5.6M | 48.89K | $114.27 | 2+ qtrs | No change |
| 66 | Crinetics Pharmaceuticalsno ticker on file | — | 0.06% | $5.3M | 103.93K | $51.10 | 2+ qtrs | No change |
| 67 | DBV Technologies S.A.DBVT · SPONSORED ADR | — | 0.05% | $5.1M | 7.31M | $0.7000 | 2+ qtrs | No change |
| 68 | KALA BIO IncKALA | — | 0.05% | $5.1M | 891.34K | $5.70 | 2+ qtrs | No change |
| 69 | Generation Bio Cono ticker on file | — | 0.05% | $4.8M | 1.94M | $2.47 | 2+ qtrs | ▲ Added 61% |
| 70 | Alector IncALEC | — | 0.05% | $4.3M | 927.26K | $4.66 | 2+ qtrs | No change |
| 71 | Prime Medicine IncPRME | — | 0.04% | $4M | 1.03M | $3.87 | 2+ qtrs | No change |
| 72 | Sagimet Biosciences IncSGMT | — | 0.04% | $3.8M | 1.38M | $2.77 | 2+ qtrs | No change |
| 73 | Structure Therapeutics IncGPCR · SPONSORED ADS | — | 0.04% | $3.8M | 85.5K | $43.89 | 1 qtr | New |
| 74 | Arcturus Therapeutics HoldingsARCT | — | 0.04% | $3.5M | 151.33K | $23.21 | 2+ qtrs | No change |
| 75 | HOOKIPA Pharma Incno ticker on file | — | 0.04% | $3.5M | 812.81K | $4.30 | 2+ qtrs | ▼ Reduced 90% |
| 76 | Leap Therapeutics Incno ticker on file | — | 0.03% | $3M | 1.17M | $2.57 | 2+ qtrs | No change |
| 77 | Enliven Therapeutics IncELVN | — | 0.03% | $2.9M | 114.83K | $25.54 | 2+ qtrs | No change |
| 78 | Compass Therapeutics IncCMPX | — | 0.03% | $2.9M | 1.56M | $1.84 | 2+ qtrs | No change |
| 79 | Wave Life Sciences LtdWVE · SHS | — | 0.03% | $2.8M | 344.06K | $8.20 | 1 qtr | New |
| 80 | Mersana Therapeutics Incno ticker on file | — | 0.02% | $2.1M | 1.09M | $1.89 | 2+ qtrs | No change |
| 81 | Newamsterdam Pharma CompanyNAMS · ORDINARY SHARES | — | 0.02% | $1.6M | 96.71K | $16.60 | 2+ qtrs | ▼ Reduced 0.1% |
| 82 | Century Therapeutics IncIPSC | — | 0.01% | $1.4M | 797.46K | $1.71 | 2+ qtrs | No change |
| 83 | vTv Therapeutics IncVTVT · CL A | — | 0.01% | $1.3M | 97.31K | $13.56 | 2+ qtrs | No change |
| 84 | Aerovate Therapeutics Incno ticker on file | — | 0.01% | $1.3M | 628.94K | $2.09 | 2+ qtrs | No change |
| 85 | Pfizer IncPFE | Health Care | 0.01% | $1M | 35K | $28.94 | 2+ qtrs | No change |
| 86 | Protara Therapeutics IncTARA | — | 0.01% | $982.4K | 536.83K | $1.83 | 2+ qtrs | No change |
| 87 | Aligos Therapeutics IncALGS | — | 0.01% | $719.3K | 83.06K | $8.66 | 2+ qtrs | — |
| 88 | BioCryst Pharmaceuticals IncBCRX | — | 0.01% | $575.9K | 75.78K | $7.60 | 2+ qtrs | No change |
| 89 | PMV Pharmaceuticals IncPMVP | — | 0.01% | $479.8K | 322.02K | $1.49 | 2+ qtrs | No change |
| 90 | Foghorn Therapeutics IncFHTX | — | 0.00% | $419.2K | 45.03K | $9.31 | 2+ qtrs | No change |
| 91 | Acrivon Therapeutics IncACRV | — | 0.00% | $370.2K | 52.89K | $7.00 | 2+ qtrs | No change |
| 92 | Tyra Biosciences IncTYRA | — | 0.00% | $249.4K | 10.61K | $23.51 | 2+ qtrs | No change |
| 93 | Surrozen Incno ticker on file · W EXP 8/11/2026 | — | 0.00% | $8.6K | 833.33K | $0.0103 | 2+ qtrs | No change |
By sector
| Sector | Share of portfolio | Value | Positions |
|---|---|---|---|
| Health Care | 75.4% | $7.3B | 22 |
| No sector on file | 24.6% | $2.4B | 71 |
Questions and answers
What did Baker Brothers own in Q3 2024?
Baker Bros. Advisors's 13F for Q3 2024 lists 93 positions worth $9.6B. The largest: ONC (24.6%), INCY (21.1%), ACAD (6.8%), SMMT (5.5%), MDGL (4.3%).
What did Baker Brothers buy in Q3 2024?
The largest purchases, by the shares bought at the quarter-end price the filing implies: INSM (added, $61.3M), CRSP (added, $34.9M), SMMT (added, $26.3M), IMVT (added, $21.7M), BCAX (new, $21.2M), PRAX (added, $11M).
What did Baker Brothers sell in Q3 2024?
The largest sales: Insmed Incorporated (sold out, $56.2M), HOOKIPA Pharma Inc (reduced, $31.5M), Cerevel Therapeutics Hldng (sold out, $28M), Athira Pharma Inc (sold out, $8.4M), Talis Biomedical Corp (sold out, $4.4M), Adaptimmune Therapeutics (sold out, $2.3M).
When was this filing made?
Baker Bros. Advisors filed its 13F for the quarter ending Sep 30, 2024 on Nov 14, 2024. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.
Learn
Cite this page
Funkfolio, “Baker Brothers portfolio, Q3 2024: Baker Bros. Advisors 13F holdings”, data as of 14 November 2024. https://funkfolio.com/gurus/baker-brothers/2024-q3
Underlying data: SEC EDGAR, Form 13F-HR of Baker Bros. Advisors (CIK 1263508) for the period ending Sep 30, 2024.
Source: SEC EDGAR, Form 13F-HR for Baker Bros. Advisors (CIK 1263508), period ending Sep 30, 2024, filed Nov 14, 2024. Changes compare share counts with the filing for Jun 30, 2024; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $9.6B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 2 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.